Clementia Pharmaceuticals Inc.
CMTA
CMTA was delisted on the 17th of April, 2019.
37 hedge funds and large institutions have $410M invested in Clementia Pharmaceuticals Inc. in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 14 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
16% more capital invested
Capital invested by funds: $353M → $410M (+$56M)
18% less funds holding
Funds holding: 45 → 37 (-8)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$20.4M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$11.4M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$5.91M |
| 4 |
JP Morgan Chase
New York
|
+$880K |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$753K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.81M |
| 2 |
PA
Perceptive Advisors
New York
|
-$6.29M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$3.86M |
| 4 |
Millennium Management
New York
|
-$3.04M |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$2.55M |
CMTA Hedge Fund Activity: Q4 2017 in Review
37 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Clementia Pharmaceuticals Inc. (CMTA) for Q4 2017, worth a combined $410M — up 16% from $353M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CMTA and 6 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 10 added.
The largest buyer was Wellington Management Group, adding an estimated $20.4M. The largest seller was Deerfield Management, exiting entirely with an estimated $7.81M sold.
- 37 institutional investors held Clementia Pharmaceuticals Inc. (CMTA) as of Q4 2017, down from 45 in Q3 2017.
- Funds reported $410M of Clementia Pharmaceuticals Inc. stock for Q4 2017, up 16% quarter-over-quarter.
- 6 funds opened new Clementia Pharmaceuticals Inc. positions in Q4 2017 and 14 closed out, a net change of -8 holders.
- The largest Clementia Pharmaceuticals Inc. buyer in Q4 2017 was Wellington Management Group, an estimated $20.4M added.
- The largest Clementia Pharmaceuticals Inc. seller in Q4 2017 was Deerfield Management, an estimated $7.81M sold.
Based on aggregated 13F filings for Q4 2017.